Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antiretroviral Analytical Treatment Interruption (ATI) to Assess Immunologic and Virologic Responses in Participants Who Received VRC01 or Placebo and Became HIV-infected During HVTN 704/HPTN 085

NCT04801758 is registered in ClinicalTrials.gov with HIV Vaccine Trials Network as lead sponsor.

NCT NCT04801758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04801758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antiretroviral Analytical Treatment Interruption (ATI) to Assess Immunologic and Virologic Responses in Participants Who Received VRC01 or Placebo and Became HIV-infected During HVTN 704/HPTN 085
Lead sponsor
HIV Vaccine Trials Network
Phase
Not applicable
Overall status
Completed
Start date
August 22, 2022
Completion date
July 22, 2024
Enrollment
18 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection